Search results
Results From The WOW.Com Content Network
Ranbaxy's Malvinder Singh remained as CEO after the transaction. [11] The addition of Ranbaxy Laboratories extended Daiichi-Sankyo's operations, with the combined company worth about US$30 billion. [12] In 2009, it was reported that former Novartis Senior Vice-President Yugal Sikri would lead the Indian operations of Ranbaxy Laboratories. [13] [14]
The company was founded in 1995 by brothers Shivinder Mohan Singh and Malvinder Mohan Singh as Specialty Ranbaxy Limited (SRL), a 50:50 joint venture between Ranbaxy Laboratories and US-based Specialty Laboratories. [5] [6] It became the first pathology company in India to receive accreditation from National Accreditation Board. [7]
Yang Hongming (Chinese: 杨鸿明), [1] more commonly known as Michael Yang in the Philippines, is a Chinese businessman and is an associate of 16th Philippine President Rodrigo Duterte. Yang was linked in the Pharmally scandal which allegedly overpriced procurement contracts for medical supplies to be used by the Philippine government during ...
For premium support please call: 800-290-4726 more ways to reach us
Get answers to your AOL Mail, login, Desktop Gold, AOL app, password and subscription questions. Find the support options to contact customer care by email, chat, or phone number.
[66] [67] In July, Teva sold off a further 42 products to Australian generics company, Mayne Pharma, for $652 million; the deal moved Mayne up 50 spots, into the top-25 companies of US generic companies. [68] As part of the deal Teva will seek to raise $20 to $25 billion [69] through a bond sale. [70]
Ranbaxy was way more than simply "laden with controversy" as currently stated in the introduction, and the Controversies section currently does not make it clear that the company's "whose business model was completely dependent on falsifying data in their drug applications to the FDA" (in the words of Katherine Eban's interviewer).
From Wikipedia, the free encyclopedia. Redirect page